Nihon Kohden, a global leader in neurodiagnostic, patient, monitoring and ventilation, today announced it is expanding the ...
In a phase 3 trial, the agent reduces seizure frequency by up to 53% in treatment-resistant focal epilepsy, with rapid onset ...
Learning Illustrator taught me patience; in therapy, that becomes pacing, titration, and resourcing to support steady, ...
Boehringer Ingelheim’s glucagon/GLP-1 dual agonist has driven 16.6% weight loss at Week 76 of a phase 3 study. While the ...
Hospitals are balancing significant cost pressures as they treat a sicker and more medically complex, aging patient ...
Azetukalner data show significant reductions in seizure frequency across weekly, monthly and multi-year time pointsX-TOLE2 data featured in ...
Is VKTX a good stock to buy? We came across a bullish thesis on Viking Therapeutics, Inc. on Charlie Evans’s Substack by ...
Higher levels of serotonin may worsen tinnitus, a new study in mice suggests. So, what does this mean for SSRI users?
Xenon Pharmaceuticals’ bull case improved after X-TOLE2 showed robust focal seizure reduction in a highly refractory patient ...
Ozempic may lead to a lower loss of lean body mass compared to Mounjaro. This may be due to tirzepatide medications, like ...
Once-weekly lonapegsomatropin shows sustained safety and efficacy up to 90 weeks in adults with GHD, according to AACE 2026 ...
MedPage Today on MSN
Navy Recruits Doctors by Appealing to Administrative Frustrations
Ad campaign has popped up in four major cities ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results